🇺🇸 LGX818 in United States

13 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 2 reports (15.38%)
  2. Nausea — 2 reports (15.38%)
  3. Renal Failure — 2 reports (15.38%)
  4. Abdominal Pain Upper — 1 report (7.69%)
  5. Acute Pulmonary Oedema — 1 report (7.69%)
  6. Back Pain — 1 report (7.69%)
  7. Basal Cell Carcinoma — 1 report (7.69%)
  8. Cholelithiasis — 1 report (7.69%)
  9. Dehydration — 1 report (7.69%)
  10. Detachment Of Retinal Pigment Epithelium — 1 report (7.69%)

Source database →

LGX818 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is LGX818 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for LGX818 in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.